ASCO 2019 – great acknowledgement of Cantargia

This year’s ASCO Annual Meeting (American Society of Clinical Oncology), one of the largest cancer congresses in the world, was a huge success for Cantargia. ASCO yearly gathers over 40 000 attendees looking for updates on recent cancer research. This year’s congress began May 31 and continued through June 4 in Chicago. Immunotherapy, the area that Cantargia is working with, is still along one of the hottest research areas with a total of 164 presentations during the congress.

Out of these 164 presentations, Cantargia’s CAN04 data was chosen as one of nine for oral presentation in the section Developmental Immunotherapy and Tumor Immunobiology. The presentation, which was called “Results from a First-in-man, Open label, Safety and tolerability Trial of CAN04 (Nidanilimab), a Fully Humanized Monoclonal Antibody against the Novel Antitumor Target IL1RAP, in Patients with Solid Tumor Malignancies”, was carried out by the principal investigator of the study, professor Ahmad Awada from Institut Jules Bordet in Brussels.

Furthermore, ASCO’s own publication ASCO Daily News selected the presentation as the highlight of the section and wrote an article based on the oral discussion that followed the presentation. The article further enhances the attention that Cantargia gets since it potentially reaches all the attendees of the congress. The article is also published online.

The CAN04 development has now reached the phase IIa for continued examination of CAN04 as monotherapy as well as in combination with standard chemotherapy.